Abstract
Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 93-99 |
| Number of pages | 7 |
| Journal | Seminars in Oncology |
| Volume | 31 |
| Issue number | 1 SUPPL. 1 |
| State | Published - Feb 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Gefitinib : Phase II and III Results in Advanced Non-Small Cell Lung Cancer. / Kelly, Karen; Averbuch, Steven.
In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 1, 02.2004, p. 93-99.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gefitinib
T2 - Phase II and III Results in Advanced Non-Small Cell Lung Cancer
AU - Kelly, Karen
AU - Averbuch, Steven
PY - 2004/2
Y1 - 2004/2
N2 - Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.
AB - Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=1242273864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1242273864&partnerID=8YFLogxK
M3 - Article
C2 - 14981586
AN - SCOPUS:1242273864
VL - 31
SP - 93
EP - 99
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 1 SUPPL. 1
ER -